Multiple sclerosis (MS) is a chronic debilitating disease that attacks the central nervous system. This study aims to investigate miR-219 and miR-155-3p expression levels involved in the myelination process following the administration of apamin peptide in the model of multiple sclerosis disease. Forty-four 8 week C57BL/6 male mice (22 ± 5 g) randomly divided into six groups. Apamin (100 µg/kg/BW) was administered intraperitoneally as a co-treatment during phase I (demyelination) or post-treatment phase II (remyelination) twice a week in cuprizone induced MS model. At the end of study myelin content and microRNA expression levels were measured with LFB staining and quantitative Real-Time PCR method, respectively. It was observed that the intended microRNAs were dysregulated during the different phases of disease induction. After 6 weeks of cuprizone exposure, miR-219 downregulated in phase I in comparison with the negative control. On the other hand, the apamin co-treatment significantly inhibit the miR-155-3p upregulation during the phase I as compared with the cuprizone group (p < 0.0001). Apamin has more impact on the miR155-3p reduction in phase I than miR-219 elevation in phase II. It could be considered as a therapeutic option for decreasing plaque formation during the exacerbation phase of the MS disease. Apamin has more impact on the miR155-3p reduction in phase I than miR-219 elevation in phase II. It could be considered as a therapeutic option for decreasing plaque formation during the exacerbation phase of the MS disease.

多发性硬化症（MS）是一种攻击中枢神经系统的慢性衰弱性疾病。这项研究的目的是研究在多发性硬化症模型中施用apamin肽后，参与髓鞘形成过程的miR-219和miR-155-3p表达水平。44只8周的C57BL / 6雄性小鼠（22±5 g）随机分为六组。在铜氮酮诱发的MS模型中，在I期（脱髓鞘）或II期治疗后（髓鞘再生）期间，每周两次腹膜内给予Apamin（100 µg / kg / BW）作为共同治疗。在研究结束时，分别通过LFB染色和定量实时PCR方法测量髓磷脂含量和microRNA表达水平。观察到在疾病诱导的不同阶段，预期的microRNA失调。铜环酮暴露6周后，与阴性对照相比，I期的miR-219下调。另一方面，与铜酮组相比，在第一阶段中，阿帕米胺的联合治疗显着抑制了miR-155-3p的上调（p <0.0001）。相较于II期miR-219升高，Apamin对I期miR155-3p降低的影响更大。它可以被认为是减少MS疾病恶化阶段斑块形成的一种治疗选择。相较于II期miR-219升高，Apamin对I期miR155-3p降低的影响更大。它可以被认为是减少MS疾病恶化阶段斑块形成的一种治疗选择。与cuprizone组相比，在第一阶段中，apaapamin联合治疗显着抑制了miR-155-3p的上调（p <0.0001）。相较于II期miR-219升高，Apamin对I期miR155-3p降低的影响更大。它可以被认为是减少MS疾病恶化阶段斑块形成的一种治疗选择。相较于II期miR-219升高，Apamin对I期miR155-3p降低的影响更大。它可以被认为是减少MS疾病恶化阶段斑块形成的一种治疗选择。与cuprizone组相比，在第一阶段中，apaapamin联合治疗显着抑制了miR-155-3p的上调（p <0.0001）。相较于II期miR-219升高，Apamin对I期miR155-3p降低的影响更大。它可以被认为是减少MS疾病恶化阶段斑块形成的一种治疗选择。相较于II期miR-219升高，Apamin对I期miR155-3p降低的影响更大。它可以被认为是减少MS疾病恶化阶段斑块形成的一种治疗选择。它可以被认为是减少MS疾病恶化阶段斑块形成的一种治疗选择。相较于II期miR-219升高，Apamin对I期miR155-3p降低的影响更大。它可以被认为是减少MS疾病恶化阶段斑块形成的一种治疗选择。它可以被认为是减少MS疾病恶化阶段斑块形成的一种治疗选择。相较于II期miR-219升高，Apamin对I期miR155-3p降低的影响更大。它可以被认为是减少MS疾病恶化阶段斑块形成的一种治疗选择。